Please use this identifier to cite or link to this item:
https://hdl.handle.net/10356/160139| Title: | Sensitivity of mycobacterium leprae to telacebec | Authors: | Lahiri, Ramanuj Adams, Linda B. Thomas, Sangeeta Susan Pethe, Kevin |
Keywords: | Science::Medicine | Issue Date: | 2022 | Source: | Lahiri, R., Adams, L. B., Thomas, S. S. & Pethe, K. (2022). Sensitivity of mycobacterium leprae to telacebec. Emerging Infectious Diseases, 28(3), 749-751. https://dx.doi.org/10.3201/eid2803.210394 | Project: | NRF-NRFI06-2020-0004 | Journal: | Emerging Infectious Diseases | Abstract: | The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis. The unprecedented potency of Telacebec against M. leprae warrants further validation in clinical trials. | URI: | https://hdl.handle.net/10356/160139 | ISSN: | 1080-6040 | DOI: | 10.3201/eid2803.210394 | Schools: | Lee Kong Chian School of Medicine (LKCMedicine) | Rights: | 2022 Public domain. Published by the Centers for Disease Control and Prevention (CDC), a U.S. Government agency. This is an open-access article distributed under the terms of the Creative Commons Attribution License. | Fulltext Permission: | open | Fulltext Availability: | With Fulltext |
| Appears in Collections: | LKCMedicine Journal Articles |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 21-0394.pdf | 1.07 MB | Adobe PDF |  View/Open |
SCOPUSTM
Citations
20
11
Updated on May 4, 2025
Web of ScienceTM
Citations
50
3
Updated on Oct 27, 2023
Page view(s)
170
Updated on May 7, 2025
Download(s) 50
62
Updated on May 7, 2025
Google ScholarTM
Check
Altmetric
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.